AbbVie will offer reduced prices for its medicines in Medicaid and commit $100 billion over the next decade to US research, development and capital investments, including domestic manufacturing
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding
MH002, a rationally designed live microbial consortium, combines six well-characterized commensal strains to target disease-specific mechanisms
The grant will fund ten new J.MD projects over the next three years, targeting multiple global health threats
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030
After leading AstraZeneca's Oncology areas nationally and internationally, Laura Colón will assume the presidency of AstraZeneca in one of its priority global markets
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
Subscribe To Our Newsletter & Stay Updated
